BR112019003579A2 - Composições de ribosídeo de nicotinamida e pterostilbeno e métodos para o tratamento dedistúrbios neurodegenerativos - Google Patents

Composições de ribosídeo de nicotinamida e pterostilbeno e métodos para o tratamento dedistúrbios neurodegenerativos

Info

Publication number
BR112019003579A2
BR112019003579A2 BR112019003579A BR112019003579A BR112019003579A2 BR 112019003579 A2 BR112019003579 A2 BR 112019003579A2 BR 112019003579 A BR112019003579 A BR 112019003579A BR 112019003579 A BR112019003579 A BR 112019003579A BR 112019003579 A2 BR112019003579 A2 BR 112019003579A2
Authority
BR
Brazil
Prior art keywords
nicotinamide
compositions
neurodegenerative disorders
methods
riboside
Prior art date
Application number
BR112019003579A
Other languages
English (en)
Inventor
Antonio Alminana Daniel
Alexander Marcotulli Eric
Original Assignee
Elysium Health Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elysium Health Inc filed Critical Elysium Health Inc
Publication of BR112019003579A2 publication Critical patent/BR112019003579A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

composições contendo uma combinação de recetor nicotinamida e pteroestilbeno para o tratamento de distúrbios neurodegenerativos, e métodos de tratamento de distúrbios neurodegenerativos utilizando estas composições e seus equivalentes são descritos. os distúrbios neurodegenerativos que podem ser tratados usando estas composições ou métodos podem incluir a doença de parkinson, doença de huntington, doença de alzheimer e semelhantes. em uma forma de realização, as composições contendo uma combinação de recetor nicotinamida e pteroestilbeno podem ser preparadas como formulações orais. em algumas formas de realização, um suplemento dietético compreende nicotinamida riboside e/ou pteroestilbeno ou equivalentes.
BR112019003579A 2016-08-22 2017-08-22 Composições de ribosídeo de nicotinamida e pterostilbeno e métodos para o tratamento dedistúrbios neurodegenerativos BR112019003579A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662378053P 2016-08-22 2016-08-22
PCT/US2017/047979 WO2018039207A1 (en) 2016-08-22 2017-08-22 Nicotinamide riboside and pterostilbene compositions and methods for treatment of neurodegenerative disorders

Publications (1)

Publication Number Publication Date
BR112019003579A2 true BR112019003579A2 (pt) 2019-05-21

Family

ID=61246253

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019003579A BR112019003579A2 (pt) 2016-08-22 2017-08-22 Composições de ribosídeo de nicotinamida e pterostilbeno e métodos para o tratamento dedistúrbios neurodegenerativos

Country Status (11)

Country Link
US (2) US11260069B2 (pt)
EP (1) EP3500267A4 (pt)
JP (1) JP7132907B2 (pt)
KR (1) KR20190046895A (pt)
CN (2) CN109982706A (pt)
AU (1) AU2017316614B2 (pt)
BR (1) BR112019003579A2 (pt)
CA (1) CA3034673A1 (pt)
MX (1) MX2019002211A (pt)
RU (1) RU2019108100A (pt)
WO (1) WO2018039207A1 (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2019002211A (es) 2016-08-22 2019-10-30 Elysium Health Inc Composiciones de nicotinamida ribosido y pterostilbeno y metodos para el tratamiento de trastornos neurodegenerativos.
CN111093676A (zh) * 2017-05-18 2020-05-01 益力舒健康公司 改善睡眠的方法和组合物
US11286274B2 (en) 2017-06-19 2022-03-29 Mitopower Llc Nicotinamide riboside derivatives and their uses
CN111542312A (zh) 2017-07-28 2020-08-14 老龄化控制中心股份公司 预防和逆转衰老方面的组合物和方法
US20220072019A1 (en) * 2018-10-19 2022-03-10 Disarm Therapeutics, Inc. Inhibitors of sarm1 in combination with nad+ or a nad+ precursor
WO2020102326A1 (en) * 2018-11-13 2020-05-22 Elysium Health, Inc Methods for determining and increasing nad levels
EP3897666A2 (en) 2018-12-17 2021-10-27 Mitopower LLC Nicotinyl riboside compounds and their uses
EP3930728A1 (en) * 2019-02-26 2022-01-05 Universitat de Valencia - Estudi General Methods and compositions for treating motor neuron diseases
CN110812365A (zh) * 2019-11-07 2020-02-21 明特奇点医疗科技（北京）有限公司 一种组合物及其制备方法与制剂
CN111838669B (zh) * 2020-08-07 2022-11-29 四川大学华西医院 治疗改善易损脏器的纳米组合物、制剂及制备方法和用途
AU2022299351A1 (en) * 2021-06-24 2024-01-04 Vestlandets Innovasjonsselskap As (Vis) Nad-augmentation therapy for parkinson's disease
WO2022269064A1 (en) * 2021-06-24 2022-12-29 Vestlandets Innovasjonsselskap As (Vis) Nad-augmentation therapy for parkinson's disease
CN118176006A (zh) * 2021-10-27 2024-06-11 益力舒健康公司 治疗更年期综合征的方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008501343A (ja) 2004-06-04 2008-01-24 ワシントン・ユニバーシティ 神経障害を治療するための方法および組成物
WO2006105440A2 (en) 2005-03-30 2006-10-05 Sirtris Pharmaceuticals, Inc. Nicotinamide riboside and analogues thereof
US20090069444A1 (en) 2007-09-07 2009-03-12 The United States Of America, As Represented By Th E Secretary Of Agriculture Method to Ameliorate Oxidative Stress and Improve Working Memory Via Pterostilbene Administration
WO2009082459A2 (en) * 2007-12-24 2009-07-02 Natrol, Inc. Anti-aging composition containing resveratrol and method of administration
WO2010095926A1 (en) 2009-02-20 2010-08-26 N.V. Nutricia Use of reveratrol for preserving cognitive functioning
EP2445488B1 (en) 2009-06-22 2020-03-18 Indus Biotech Private Limited Process for obtaining purified pterostilbene and methods of use thereof
NZ598290A (en) 2009-07-24 2014-12-24 Amazentis Sa Compounds, compositions and methods for protecting brain health in neurodegenerative disorders
US9439875B2 (en) 2011-05-11 2016-09-13 The United States Of America, As Represented By The Secretary Of Agriculture Anxiolytic effect of pterostilbene
EP2574339A1 (de) 2011-09-27 2013-04-03 Johannes Huber Pharmazeutisches Präparat zur Behandlung von NADH-bedingten Erkrankungen
US20130149277A1 (en) 2011-12-13 2013-06-13 Cliffstar Llc Pterostilbene and pvp grape juice extract combination for treatment of metabolic, vascular, and neurodegenerative disorders
US20130296440A1 (en) 2012-05-01 2013-11-07 ChromaDex Inc. Pterostilbene and curcumin combination for treatment of oxidative stress and inflammation
KR20220098049A (ko) * 2013-10-30 2022-07-08 크로마덱스 아이엔씨. 피부 질환 치료에서의 국소적 사용을 위한 니코틴아미드 리보사이드 조성물
CN106536535A (zh) 2014-06-02 2017-03-22 葛兰素史密斯克莱知识产权（第2 号）有限公司 结晶的β‑D‑烟酰胺核苷的制备和用途
WO2016122832A1 (en) * 2015-01-30 2016-08-04 Natural Formulations Compositions, therapeutic and prophylactic methods for treatment of neurodegenerative diseases and brain injuries
WO2016149277A1 (en) * 2015-03-17 2016-09-22 Specialty Nutrition Group, Inc. Nutritional compositions to enhance mitochondrial energy production
MX2019002211A (es) 2016-08-22 2019-10-30 Elysium Health Inc Composiciones de nicotinamida ribosido y pterostilbeno y metodos para el tratamiento de trastornos neurodegenerativos.

Also Published As

Publication number Publication date
US20190201426A1 (en) 2019-07-04
AU2017316614B2 (en) 2023-06-15
CN109982706A (zh) 2019-07-05
AU2017316614A1 (en) 2019-03-21
EP3500267A4 (en) 2020-03-18
CA3034673A1 (en) 2018-03-01
JP7132907B2 (ja) 2022-09-07
WO2018039207A1 (en) 2018-03-01
RU2019108100A3 (pt) 2020-11-27
KR20190046895A (ko) 2019-05-07
JP2019524856A (ja) 2019-09-05
US11260069B2 (en) 2022-03-01
US20220143055A1 (en) 2022-05-12
CN115645432A (zh) 2023-01-31
US11998561B2 (en) 2024-06-04
MX2019002211A (es) 2019-10-30
RU2019108100A (ru) 2020-09-22
EP3500267A1 (en) 2019-06-26

Similar Documents

Publication Publication Date Title
BR112019003579A2 (pt) Composições de ribosídeo de nicotinamida e pterostilbeno e métodos para o tratamento dedistúrbios neurodegenerativos
PH12019500521A1 (en) Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer
CO2019013707A2 (es) Polinucleótidos de aadc para el tratamiento de la enfermedad de parkinson
ZA201800056B (en) Nicotinamide riboside and pterostilbene compositions and methods for treatment of skin disorders
MX2022005225A (es) Derivados de benzooxazol como inmunomoduladores.
EP4272834A3 (en) Therapeutic use of mitochondria and combined mitochondrial agents
BR112017009497A2 (pt) polinucleotídeos de aadc para o tratamento da doença de parkinson
MX2017013562A (es) Reguladores de microbioma y usos relacionados de los mismos.
BR112017007063A2 (pt) ?composições e métodos para o tratamento de insônia?
MX2019004859A (es) Tratamientos de combinacion que comprenden la administracion de imidazopirazinonas.
MX2018008645A (es) Derivados de 8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano.
CY1125113T1 (el) Συνθεσεις και μεθοδοι για χρηση στην αγωγη της ομοκυστινουριας
PT3302454T (pt) Composições para utilização no tratamento da doença de parkinson e distúrbios associados
PH12016501371A1 (en) Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same
MX2018001592A (es) Composiciones y metodos para el tratamiento y la prevencion de trastornos neurodegenerativos.
BR112017002260A2 (pt) derivados de piperazina como moduladores do receptor x do fígado
WO2018013951A9 (en) Targeting adenosine a2a receptors for the treatment of levodopa-induced dyskinesias
BR112017023539A2 (pt) composições para limpeza de cólon e tratamento de distúrbios gastrointestinais
EP3554496A4 (en) METHODS AND COMPOSITIONS FOR TREATING PARKINSON'S DISEASE
EP3628008A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF ALZHEIMER'S DISEASE
IL265911A (en) Epilimod preparations and methods of using them in the treatment of Alzheimer's disease
HK1258884A1 (zh) 用於治療竇疾病和病症的組合物和方法
EP3518914A4 (en) COMPOSITIONS AND METHODS FOR TREATING ALZHEIMER'S DISEASE AND PARKINSON'S DISEASE
EP3344239A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF PARKINSON'S DISEASE
BR112017009599A2 (pt) composições contendo apoaequorina e métodos de uso das mesmas para tratar inflamação neuronal

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]